TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02918578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone group
Description: Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone and SMS group
Description: The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single writing group
Description: The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone.
Study: NCT02652403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete conventional dentures
Description: The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete simplified dentures
Description: For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
Study: NCT00569595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Stimulating Disease Prevention Program
Description: The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Fighting Cancer with Advice
Description: Patient health counseling program by lay health educators entitled Fighting Cancer with Advice.
Study: NCT02796560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand name travoprost
Description: Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic travoprost
Description: Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
Study: NCT00596778

Intervention type: OTHER
Group type: OTHER
Intervention: chest physiotherapy
Description: The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
Study: NCT01414374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal medicine
Description: Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
Study: NCT03905161

Intervention type: OTHER
Intervention: 6-minute walk test
Description: The 6-minute walk test (6MWT) is widely used in the clinic to measure treatment efficacy and disease progression in patients with neuromuscular diseases and is found valid and reliable to measure decrease in walking speed for neuromuscular patients.
Study: NCT01084655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.
Study: NCT02037971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
Study: NCT04589429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine 10 MG/ML
Description: intrathecal morphine 300 micrograms
Study: NCT01622166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychodynamic art therapy
Description: 2 sessions à 1.5 hrs /week, intervention duration 6 weeks
Study: NCT03399019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: initial loading dose (0.5 \~ 1㎍/kg for 10 minutes) and maintenance infusion (0.2-0.7㎍/kg/hr)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: continuous infusion (0.75-3mg/kg/hr)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.05mg/kg bolus injection and if not OAA/S ≤ 3 within 5 minutes, add 0.01mg/kg at intervals of 1\~2 minutes
Study: NCT04589429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 10 MG/ML
Description: intrathecal morphine 300 micrograms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine Hydrochloride 10 MG/ML
Description: intrathecal nalbuphine 2mg.
Study: NCT00494481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib (ZD6474)
Description: once daily oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion
Study: NCT01030198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RevLite (Laser Treatment)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RevLite (Laser Treatment)
Study: NCT00637923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: One weekly injection of 180µg of peginterferon α-2a for 48 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: One weekly injection of 180µg of peginterferon α-2a for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Weight-based ribavirin for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Weight-based ribavirin for 48 weeks.
Study: NCT00867282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: PF-00241939 750ug using inhaler A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: PF-00241939 750ug using inhaler B
Study: NCT02097641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells
Description: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasma-Lyte A
Description: Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.
Study: NCT02709824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate with ADS
Description: Oral rinsing, twice a day, for 21 days
Study: NCT03959891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
Study: NCT02709824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate without ADS
Description: Oral rinsing, twice a day, for 21 days
Study: NCT00680589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of mouse TYRP2 DNA
Description: Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
Study: NCT04047589

Intervention type: BEHAVIORAL
Intervention: Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
Description: Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
Study: NCT01456039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
Study: NCT05990010

Intervention type: DIAGNOSTIC_TEST
Intervention: Berlin Questionnaire
Description: The Berlin Questionnaire is a simple survey that helps doctors identify OSA risk. It looks at snoring, daytime sleepiness, obesity, and hypertension. A positive score in two or more areas indicates high risk, while one or none suggests low risk. It is an easy and effective tool to assess OSA risk, with proven validity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Berlin Questionnaire
Description: The Berlin Questionnaire is a simple survey that helps doctors identify OSA risk. It looks at snoring, daytime sleepiness, obesity, and hypertension. A positive score in two or more areas indicates high risk, while one or none suggests low risk. It is an easy and effective tool to assess OSA risk, with proven validity.
Study: NCT01021020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6mg tablet administered after a fast of at least 10 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6mg tablet administered after a standardized high-fat, high-calorie breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine/Probenecid
Description: 0.5mg/500mg tablet administered after a fast of at least 10 hours
Study: NCT04693819

Intervention type: DIAGNOSTIC_TEST
Intervention: Somatic modulation
Description: Type of modulations: 3 jaw and 6 cervical spine modulations, 1 control movement (i.e. without any expected somatic modulation effect) Jaw modulations: laterotrusion to the left, laterotrusion to the right and protrusion Cervical spine modulations: isometric flexion, extension and left and right lateroflexion of the head against resistance of the investigator's hand, compression and traction of the cervical spine in sitting position.~Control movement: the investigator's hand rests against the patient's forehead without any force application
Study: NCT04047589

Intervention type: BEHAVIORAL
Intervention: Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations
Description: Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future
Study: NCT01454518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltration of local anesthetic
Description: 30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Injection
Description: injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
Study: NCT03048643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient parenteral antibiotic therapy
Description: Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
Study: NCT02669420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: termination of second trimester pregnancy
Description: Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: termination of second trimester pregnancy
Description: Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
Study: NCT00690235

Intervention type: DRUG
Group type: OTHER
Intervention: Pramlintide
Description: 180mg subcutaneous injections, twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 180mg subcutaneous injections, twice daily
Study: NCT04012229

Intervention type: GENETIC
Intervention: BRCA mutation
Description: The genetic testing was performed according interregional consensus (Manchester score \> or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
Study: NCT04191044

Intervention type: OTHER
Intervention: A complete cardiovascular and liver characterization will be carried out
Description: A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.

Intervention type: OTHER
Intervention: A complete cardiovascular and liver characterization will be carried out
Description: A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.

Intervention type: OTHER
Intervention: A complete cardiovascular and liver characterization will be carried out
Description: A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.

Intervention type: OTHER
Intervention: A complete cardiovascular and liver characterization will be carried out
Description: A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
Study: NCT01893437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6799477
Description: Single doses of RO6799477
Study: NCT05475652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The manual therapy intervention is performed twice on the experimental group, once on day 0 (D0) and the second time on day 7 (D7). This intervention consists of a manual therapy protocol (base on myofascial release) applied to the cervical spine. Protocol consists of succession of techniques: suboccipital decompression, disengagement of Cervical 0-1-2,vibratory stimulation at C4 level and myofascial release technique of the cervical aponeuroses. Outcomes are evaluated before and after intervention.The same schedule will be reproduced on D7. On D21, only one assessment will be done at the beginning of the session.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo intervention
Description: The Sham group receives placebo treatment twice (D0 and D7). This placebo treatment also called light touch treatment consists of applying light pressure with broad support from both hands on either side of the joint, in contact with the skin, without equal bone pressure or therapeutic intention, for a duration comparable to that of manual therapy. Outcomes are evaluation before and after placebo intervention. The same schedule will be reproduced at D7. On D21, only one assessment will be done at the beginning of the session and a manual therapy treatment on the cervical spine is provided to balance access to care in the two group
Study: NCT03019796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDICATION AND EXERCISE TRAINING
Description: PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDICATION AND EXERCISE TRAINING
Description: PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE).
Study: NCT01491893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Study: NCT02499770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study: NCT02739373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986189

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo